# CLL11 (NCT01010061)

> CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

No report yet. It can be ordered.

- Drugs tested: obinutuzumab
- Indication: previously untreated chronic lymphocytic leukemia with comorbidities

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01010061
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Lymphocytic Leukemia, Chronic
- Interventions: obinutuzumab; rituximab; chlorambucil
- Enrollment: 787
- Primary outcome: Progression-free Survival (PFS)
- Primary outcome: Percentage of Participants With Progression Free Survival Events

## Indexed commentary on CLL11 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 15 posts on X
- 8 YouTube videos
- 5 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cll11-nct01010061

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01010061", "email": "<work email>"}; the inbox owner confirms by the emailed link.